Since the first Marburg virus disease (MVD) outbreak in 1967, a preventive vaccine has not been available. An innovative vaccine candidate is now being tested in the United States.
Announced on April 16, 2025, the Albert B. Sabin Vaccine Institute recently launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, based on the cAd3 platform, administering doses to the first participants in Melbourne, Florida.
In addition to Melbourne, the vaccine will soon be tested at sites in Dallas, Texas; Huntsville, Alabama; and Peoria, Illinois.
Read More
